Bill Melinda Gates Foundation Logo

GAITHERSBURG, Md.June 5, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, has signed a three-year agreement with the Bill & Melinda Gates Medical Research Institute to provide its adjuvant for use in preclinical vaccine research.

"We are excited to partner with the Bill & Melinda Gates Medical Research Institute to include our unique technology in their public health-focused vaccine research efforts," said John C. Jacobs, President and Chief Executive Officer, Novavax. "Our Matrix-M™ adjuvant is proven to enhance and broaden the immune system response when included in vaccines and is already a key component of COVID and malaria vaccines on the market today. We look forward to partnering more broadly with a variety of organizations so that our technology can benefit vaccine development across many disease areas."

"The Bill & Melinda Gates Medical Research Institute is committed to developing biomedical interventions that address global health concerns for those in the greatest need," said Emilio Emini, PhD, chief executive officer of the Bill & Melinda Gates Medical Research Institute. "We look forward to working with Novavax's Matrix-M™ adjuvant in some of our early-stage vaccine programs."


The CBRE Life Sciences Research Talent 2023 Report underscores the BioHealth Capital Region's consistent position in the top three hotspots for life sciences talent in the United States. The report reveals a booming life sciences industry, with a record number of individuals graduating with degrees in biological and biomedical sciences. Over the past two decades, the number of life science professionals in the U.S. increased by 79%, in contrast to the 8% growth rate across all other occupations. This trend has led to the fastest pace of industry growth on record, particularly rebounding after a downturn in 2020.

Among the specific roles and jobs within the sector, medical scientists have seen the greatest increase. However, the report also notes a fierce competition for talent, with the industry facing a "furious search for talent" to meet escalating demands for its products and services. Despite this overall growth and competitiveness across the country, the BioHealth Capital Region stands out for its ability to attract and retain top talent, as evidenced by its position in the top three.


Charlottesville, VA - June 2, 2023 - The Charlottesville Business Innovation Council (CBIC) has awarded AMPEL BioSolutions, a leading data science company, with the prestigious "Innovator-of-Year" title. The recognition was given to AMPEL BioSolutions for the outstanding AMPEL Genomic Platform, which utilizes RNA analytics and Machine Learning for dynamic disease management, including flare prediction and personalized decision support for drug options.

AMPEL BioSolutions is currently in commercialization mode and making significant progress in executing its platform technology. This year, AMPEL is set to make LuGENE, a blood test, available nationwide in the United States through ReLATE. The CBIC award ceremony was a moment of celebration for the AMPEL team, who thanked Angel Williams Derricott, for her unwavering Advocacy for Lupus & celebrating with the AMPEL team at CBIC unwavering advocate for Lupus, joined.

MoCo Life Sci2

The life sciences industry is seeing tremendous growth in Maryland, particularly in the D.C. suburb of Montgomery County. With nearly $6B invested in life sciences ventures in 2021 alone and more than 40,000 life sciences workers in the state, Montgomery County is the anchor of the fourth-largest biotech hub in the U.S.

The county’s life sciences market continues to expand its footprint with more biotech and pharmaceutical companies setting up shop in Rockville and other areas, drawn in by its skilled workforce. Also fueling the growth is the Montgomery County Economic Development Corp., which helps companies expand, relocate or start in the county. 

“We have the skilled labor force, the support of local universities, the Maryland Tech Council and a diverse population to help expand life sciences not only in Montgomery County but the state of Maryland,” MCEDC Senior Vice President of Business Development Brad Stewart said.

Precigen Logo

Precigen Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer
Published: May 31, 2023

– HPV is responsible for more than 90 percent of cervical cancer cases globally with approximately 300,000 women living with cervical cancer in the US –

– Current response rates to second line treatments in recurrent or metastatic cervical cancer are very low and associated with a high rate of toxicity –

– PRGN-2009 is designed to generate de novo T-cell immune response against HPV 16/18-positive solid tumors cells and is differentiated from other platforms due to the ability of gorilla adenovectors to enable repeat administrations –

– PRGN-2009 Phase 1 data to be presented at the 2023 ASCO annual meeting on June 3 (Abstract # 2628); PRGN-2009 in combination with a checkpoint inhibitor demonstrated a favorable safety profile and resulted in a 30% ORR in patients with heavily pre-treated HPV-associated cancers, including those who have previously failed checkpoint inhibitors –

– Phase 2 study of PRGN-2009 is in combination with pembrolizumab in the second line setting in patients with recurrent or metastatic cervical cancer previously treated with pembrolizumab for recurrent or metastatic disease –

– CMC path in place to support delivery of product for Phase 2 study as well as future framework to support potential pivotal trials –


Entrepreneurs-in-Residence (EIR) Team Continues Growth With National Institutes of Health (NIH)

ROCKVILLE, MARYLAND, May 30, 2023 BioHealth Innovation Inc. (BHI) proudly welcomes Claire Leurent, Ph.D. MBA, to its expanding Entrepreneurs-in-Residence (EIR) team. As part of BHI’s commitment to advancing disruptive technologies in healthcare, the Entrepreneur-in-Residence Program ensures that these innovations receive the necessary resources to transition from discovery to commercialization and make a measurable impact on human health. Claire will collaborate with the NIH Seed Program, supporting scientists, early-stage startups, and licensed technologies.

“We are excited to have Claire Leurent join our EIR team as we continue our collaboration with the National Institutes of Health,” said Richard Bendis, President and CEO of BHI. “Claire’s extensive expertise in venture capital investment and drug development perfectly aligns with our mission to drive innovation and transformative healthcare solutions.”

With a venture capital investor background and hands-on experience leading drug development from scientific discovery to registration studies, Claire Leurent is driven by her passion for science and dedication to improving lives through transformative technologies and business models. Her dynamic perspective and commitment to progress make her an invaluable addition to the BHI team.

MSCRF Black Transparent

What do you get when you combine a networking happy hour for STEM researchers, an engaging expert panel discussion and a host of exciting STEM inventions? The answer is one exciting event: the Maryland Innovation Initiative’s Pop-up at the University of Maryland, College Park (UMD) and Innovate Maryland: Invention of the Year Awards!

TEDCO and the Maryland Innovation Initiative (MII) were on hand to sponsor Innovate Maryland’s Invention of the Year Awards, held at The Hall on the University of Maryland’s College Park campus. Innovation was all around, encompassed by the various finalists and the Invention of the Year winner: a solar-powered system that uses all-natural, partly plant-based materials to extract drinkable water from the toughest environments.

Maryland is home to many talented researchers — in fact, it has the highest concentration of Ph.D.s of any state in the country, while also ranking #1 for its technology and science workforce. The MII recognizes the commercial possibilities coming out of the state’s creative faculty and supports these innovators by serving as a catalyst to both spur exciting startup projects at Maryland’s research universities and ignite an entrepreneurial mindset among faculty. Both of these elements were on

Click here to read more via


On May 26, 2023, Emergent BioSolutions Inc. (including its wholly-owned subsidiaries, “Emergent”), through its wholly-owned subsidiary, Emergent Product Development Gaithersburg Inc., received a contract modification from the Office of the Assistant Secretary for Preparedness and Response (“ASPR”), an agency of the U.S. Department of Health and Human Services (“HHS”), exercising and funding the third of nine annual contract term extension options (the “Third Option Exercise”) for Emergent to supply ACAM2000® (Smallpox (Vaccinia) Vaccine, Live) into the U.S. Strategic National Stockpile (the “SNS”). The Third Option Exercise is valued at approximately $120 million.

The Third Option Exercise was made under a bilateral modification of Emergent’s existing 10-year contract (the “Contract”) awarded by ASPR on August 30, 2019. The period of performance under the Third Option Exercise requires Emergent to deliver doses of ACAM2000 into the SNS by June 30, 2023.

The preceding description of the Third Option Exercise does not purport to be complete and is qualified in its entirety by reference to the Third Option Exercise. The Third Option Exercise, with relevant redactions to protect confidential and sensitive information, is expected to be filed as an exhibit to Emergent’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2023. The Contract is filed as a material agreement of Emergent as exhibit 10.48 with Emergent’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019.

HeMemics Logo

GAITHERSBURG, Md.May 25, 2023 /PRNewswire/ -- Hememics Biotechnologies, Inc., developer of first-in-class, handheld, multiplexed biosensor platform that can test antibodies, antigens and molecular targets simultaneously, announced today the closing of a $2 million Seed 2 financing round. Participants of this round include a strategic investor, existing investors and Maryland Technology Development Corporation (TEDCO).

"I am extremely proud of what the company has achieved with the limited amount of resources," said John Warden, Jr., CEO and Co-founder of Hememics Biotechnologies, Inc. "We have generated extremely favorable results from more than 100,000 biosensor experiments in the past nine months. The new funding will allow us to finalize our design, receive third-party validation, and develop early commercial customers." 


GAITHERSBURG, Md.--(BUSINESS WIRE)--Adaptive Phage Therapeutics, Inc. (APT), a clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, is pleased to announce a collaboration and license agreement with the Israeli Phage Therapy Center (IPTC) of the Hebrew University of Jerusalem and Hadassah Medical Center. Researchers at the IPTC have discovered several phages that have exceptionally broad coverage against antibiotic resistant bacteria. Under the agreement, Hadasit and Yissum, the technology transfer companies of Hadassah and the Hebrew University, grants APT exclusive rights to make, use, and sell licensed phages for human therapy, with the right to sublicense through multiple tiers. APT also has the first right to evaluate additional phages discovered by IPTC researchers for inclusion in APT’s phage bank. As consideration for the license and first right of refusal, APT made an upfront payment and will pay royalties from net sales on any therapeutic composition comprising a licensed phage.


Rockville, MD, United States, May 23, 2023 – Advanced BioScience Laboratories (ABL), a global Contract Development and Manufacturing Organization (CDMO) for biotherapies,
oncolytics and viral vector vaccines, today announces it has been awarded a contract for ‘Resources to Advance Pediatrics and HIV Prevention Science (RAPPS)’ by the Division of AIDS
(DAIDS) within the National Institute of Allergy and Infectious Disease (NIAID) at the National Institutes of Health (NIH).

This seven-year contract has a total potential funding value of $98.9 million. ABL will provide DAIDS with (i) preclinical gap-filling, (ii) animal models, (iii) bioanalytical services, (iv)
product manufacturing and (v) other scientific and quality/regulatory services to support preclinical research, development of pediatric formulations and advancement of next generation non-vaccine Biomedical HIV Prevention products (nBPs) such as IntraVaginal Rings (IVRs), long-acting injectables and Multipurpose Prevention Technologies (MPTs) composed of a combination of drugs that can target prevention of pregnancy, Sexually Transmitted Infections (STIs) and/or HIV.


ROCKVILLE, Md.May 23, 2023 /PRNewswire/ --REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for RGX-121, an investigational one-time AAV Therapeutic for the treatment of Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome. RMAT designation is designed to expedite the drug development and review processes for promising new treatments, including gene therapies, and recognizes that the preliminary clinical evidence from RGX-121 indicates its potential to address unmet medical needs for MPS II. RGX-121 is currently being studied in the CAMPSIITE™ trial that is enrolling MPS II patients as part of a pivotal program that incorporates material from the NAVXpress™ platform process manufactured at the REGENXBIO Manufacturing Innovation Center and continues to support plans to file Biologics License Application (BLA) in 2024 using the accelerated approval pathway.


COLUMBIA, Md. (May 23, 2023) – TEDCO, Maryland’s economic engine for technology companies, announced a Venture Funds investment of $300,000 into Pathotrak, a biotechnology company.

Javier Atencia“Until Pathotrak, producers would need to wait for the results of pathogen tests, leading to costly warehousing and refrigeration costs,” said Javier Atencia, CEO and founder of Pathotrak. “Through our innovative solution, we are eliminating this need by cutting down the time it takes to get results, which will also help prevent costly recalls and food waste.”

Pathotrak, based in College Park, Md., is a business with the mission to create a world with fresher and safer food using cost-efficient innovative technology. This technology will allow the expedition of foodborne pathogen detection, providing companies and producers with faster results, and ultimately shortening what is typically a 22-hour process down to under six hours. This rapid detection process has the potential to decrease food waste, allowing products to be placed on shelves up to an entire day earlier while also reducing the costs of food production—from the costly warehousing and refrigeration processes to the expensive recalls.


Maryland medical device company supports patients and medical professionals through safer needle filtration device

COLUMBIA, Md. (May 22, 2023) – TEDCO, Maryland’s economic engine for technology companies, announced a recent Seed Funds investment of $250,000 into CarrTech Corp., a medical device company. TEDCO’s Seed Funds invest in early-stage, technology and life sciences companies and provides access to gap financing.

“The current eight-step process healthcare professionals are required to take to administer certain medicine is inefficient and high-risk of needlestick injuries and glass shard contamination to the patient,” said Sue Carr, founder of CarrTech Corp. “By eliminating the need to attach and detach multiple needles, patients are able to get access to the medication they need faster and safer.”

The most recent round of seed funding came from its Life Science Investment Fund; investments are for companies in the process of developing a technology for a product for human health that requires approval from the United States Food and Drug Administration prior to market.


Pharmacy Times® interviewed Harsha Rajasimha, PhD, founder and CEO of Jeeva Informatics, on the potential to accelerate patient recruitment and solve clinical trial delays. Currently, the research, development, and approval process of a new drug by the FDA can take between 12 to 15 years. However, studies have shown patient recruitment issues are the cause of 85% of clinical trial delays.

Pharmacy Times: What are the different phases of the drug approval process by the FDA?

Harsha Rajasimha: Typically, drug approval process involves a preclinical phase, which enables first-in-human clinical trial for a new drug or entity. And that goes through phase 1, phase 2, phase 3 trials, typically. And sometimes there can be phase 1 and 2, or phase 2 and 3 combined, and stuff like that, and different types of trial designs these days, but typically phase 1, phase 2, phase 3, where phase 1 is entirely looking at safety of the drug in humans, because it's only tested in animals. Phase 2, looking at safety and efficacy at very low doses to make sure there is some drug effect. And phase 3 is full-fledged in a larger population, to assess the safety and efficacy profile across the range of doses in a range of patients in the target population. And after that, all of this data gets wrapped into an FDA submission for review. And the whole process from phase 1 to phase 3 and the review process can take about 7 years, typically, sometimes longer. And so, it's a very expensive and time-consuming process. And this process is often called the “Valley of Death,” because only 1 in 9, 1 out of 10 drugs actually make it through the regulatory approval. Most of them will fail at phase 1, or phase 2, or phase 3, about 30% at each phase. So, very few drugs make it to market.


Maryland-based business protecting individuals and businesses from environmental hazards through the use of its innovative sensor technology

COLUMBIA, Md. (May 22, 2023) – TEDCO, Maryland’s economic engine for technology companies, announced a recent State Small Business Credit Initiative (SSBCI) investment of nearly $400,000 into N5 Sensors, Inc. This SSBCI investment was made through TEDCO’s Seed Funds

“Environmental hazards are not always preventable, but detecting these hazards can support the safety of everyone in the area,” said Abhishek Motayed, Ph.D., CEO of N5 Sensors. “I’m thankful for TEDCO’s interest and support—with this additional funding, we can continue our research and find new ways to help provide safety to everyone.”

N5 Sensors, based in Rockville, Md., is a startup company with a mission to keep people safe form environmental hazards. This process is done using a cloud-connected ecosystem of smart sensors that utilize and leverage the endless possibilities of shared data and artificial intelligence. Through this approach, the company has developed a variety of products and solutions, each with the goal of helping individuals stay safe from various environmental hazards.

Rich and Amrie 250

Can you envision a world where precision medicine transforms healthcare as we know it? Tune in to this exciting episode of BioTalk with Rich Bendis, featuring Dr. Amrie Grammer, Co-Founder of AMPEL BioSolutions. In this enlightening discussion, Dr. Grammer unveils the secrets behind AMPEL's remarkable success in precision medicine, making this episode a must-listen. Learn about the groundbreaking genomic tests developed by AMPEL, providing decision support for autoimmune diseases, and delve into the role of artificial intelligence in predicting potential treatments.

Explore the immense potential for a revolution in healthcare as Dr. Grammer shares insights on understanding the human genome and AMPEL's cutting-edge work in harnessing Big Data and Machine Learning for personalized precision medicine. Don't miss this great episode and gain valuable insights into the future of data-driven health.

Listen now via your favorite podcast platform


RICHMOND, VA – May 18, 2023 – The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $2 million in grants to four life and bioscience projects in the Commonwealth of Virginia, pending execution of the grant agreements. These grants, which will be met with significant matching funds from partner companies, were awarded through Grant Round 14 of Virginia Catalyst’s ongoing mission to stimulate economic development by promoting collaborative projects that address large, unmet needs for improving human health, and that can create high-paying jobs in the Commonwealth.


PQE Group receives certification in the U.S. as a work environment where “you trust the people you work for, take pride in what you do, and have fun with the people you work with.”

May 18, 2023, Washington DC — PQE Group US is proud to be Certified™ by Great Place To Work® for the second year in a row. This esteemed recognition is solely based on the feedback of our present employees regarding their work experience at PQE Group. This year, a remarkable 91% of our employees expressed their satisfaction with their workplace, which is 34 points higher than the average U.S. Company.
Great Place To Work® is the global authority on workplace culture, employee experience, and the leadership behaviors proven to deliver market-leading revenue, employee retention and increased innovation. "Great Place to Work Certification is a highly coveted achievement that requires consistent and intentional dedication to the overall employee experience," says Sarah Lewis-Kulin, the Vice President of Global Recognition at Great Place To Work. She emphasizes that Certification is the sole official recognition earned by the real-time feedback of employees regarding their company culture. “By successfully earning this recognition, it is evident that PQE Group stands out as one of the top companies to work for, providing a great workplace environment for its employees."


Baltimore, Maryland--(Newsfile Corp. - May 17, 2023) - Flavocure Biotech, Inc. ("Flavocure"), today announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase I, first-in-human clinical study of Caflanone (FBL-03G) for the treatment of pancreatic cancer. Pancreatic Ductal Adenocarcinoma (PDAC) accounts for about 2% of all cancers and is associated with 5% of cancer‐related deaths. Caflanone treatment is combined with radiotherapy (RT) for enhanced efficacy against cancer cells.

"We are thrilled to obtain clearance to advance Caflanone (FBL-03G) into clinical trials and are excited about the prospects of what this new class of therapeutic agent may mean for cancer patients," said Dr. David G. Brooks, MD, Ph.D., Interim Chief Medical Officer of Flavocure Biotech, Inc. "This is an important milestone for our company, representing our first program to receive FDA clearance to proceed into a clinical trial. This new approach combining radiotherapy with our lead drug candidate, caflanone, leverages our groundbreaking science and has broad potential applicability in many therapeutic areas," said Dr. Ngeh J. Toyang, Ph.D., Chief Executive Officer and co-Founder of Flavocure Biotech, Inc.


ROCKVILLE, Md., May 16, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that preclinical research in Mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio syndrome, was selected for inclusion in the Foundation for the National Institutes of Health Accelerating Medicines Partnership® Bespoke Gene Therapy Consortium (AMP® BGTC), clinical trial portfolio. The Consortium brings together partners such as NIH and FDA, as well as partners from private and non-profit sectors.

Sponsored by Nemours Children's Hospital, MPS IVA is one of eight programs selected as part of AMP® BGTC's first clinical portfolio to help accelerate the development of bespoke gene therapies, with the goal of streamlining the regulatory approval process. MPS IVA is a metabolic condition that primarily affects the skeleton, and is estimated to impact 1 in 200,000 to 300,000 individuals.

Dr. Monica Bertagnolli

Today (May 15, 2023), President Biden announced his intent to nominate Dr. Monica Bertagnolli as Director of the National Institutes of Health (NIH), the world’s preeminent biomedical research organization. Dr. Bertagnolli is a world-renowned surgical oncologist, cancer researcher, educator, and physician-leader who has the vision and leadership needed to deliver on NIH’s mission to seek fundamental knowledge and promote human health.  

Statement from President Biden: “Dr. Bertagnolli has spent her career pioneering scientific discovery and pushing the boundaries of what is possible to improve cancer prevention and treatment for patients, and ensuring that patients in every community have access to quality care.

As Director of the National Cancer Institute, Dr. Bertagnolli has advanced my Cancer Moonshot to end cancer as we know it. She has brought together partners and resources from different sectors to launch groundbreaking efforts in cancer prevention and early detection, a national navigation program for childhood cancers, and additional programs to bring clinical trials to more Americans.

Dr. Bertagnolli is a world-class physician-scientist whose vision and leadership will ensure NIH continues to be an engine of innovation to improve the health of the American people.”


Reimbursement is key to the success of innovators who have products, therapies, and new modes of service for expectant and new mothers. Not only is it key to have the codes and contracts that are critical to billing, the payors themselves (both commercial and Medicaid) open the door to meeting the moms and babies for whom the products are intended.

Anna Zornosa (seated on the right), EIR with both BHI and the NIH, moderated a panel featuring three OB GYNS who represent key sectors of the reimbursement ecosystem: Dr. John Keats (first on the left), a maternal health expert with Cigna, represented the commercial insurer viewpoint; Dr. Barbara Levy, vice-chair of the  AMA’s CPT panel, represented the view of how codes are established; and Dr. Miguel Fernandez (third from the left), spoke of his experience with Medicaid programs as Chief Medical Officer of Aetna Better Health of Florida. The three concurred that innovators need to lead with data showing the impact of their innovations on patients’ outcomes as the basis of initial conversations. The lively panel brought to life examples of successful innovator-reimbursement partnerships and responded to dozens of audience questions.


Ethel Rubin, Ph.D., an Entrepreneur-in-Residence at BioHealth Innovation, Inc. (BHI), recently participated in a “CEO Roundtable” for JLABS @ NYC. The discussion revolved around various financing strategies for biotech companies. In addition to Dr. Rubin, the roundtable also featured Sally Allain, MBA, M.S., Head of JLABS @ Washington, DC, and Board Member of BHI. Her participation added further depth to the discussion, bringing in her unique insights and experiences in the biotech sector.

The roundtable brought together CEOs from the biotech sector to discuss various topics. These included the different types of investors in the biotech space and strategies for identifying and engaging with them. The participants also delved into the concept of an investment thesis, a guiding principle that dictates the kind of opportunities investors seek.


Renée JG Arnold, PharmD, RPh, who serves as an Entrepreneur-in-Residence at BHI NHLBI EIR, recently moderated and participated in a panel discussion at the 28th Annual International meeting of ISPOR, which was held on May 8, 2023 in Boston. The panel, titled “Blazing the Trail for Digital Health Innovation: Resources and an Example Based on a Digital Health Application for Dementia Family Caregivers,” was attended by 75 delegates and focused on various aspects of digital health application development. Topics included the challenges and opportunities associated with the development of digital health applications, available NIH grants and product development resources, real-world experience in developing digital health solutions, and emerging regulations in the US for digital health.

After the panel discussion, Arnold and the other panelists continued the conversation with 15 attendees in a separate venue, where they further explored various aspects of digital health applications. Other panelists included Kathleen Rousche, PhD, Director of the Innovation & Commercialization Office at NHLBI; Eric Jutkowitz, PhD, an Associate Professor at Brown University; and Anindita (Annie) Saha, the Assistant Director of the Digital Health Center of Excellence at the US Food and Drug Administration.


Women In Bio is proud to announce that Gina Ford has joined our team as Executive Director. Gina brings a wealth of experience, having worked in the life science and non-profit industries for years. She is a champion of women in the sciences, and we are thrilled to have her guide WIB into the future. 

As WIB nears the conclusion of its latest 3-year Strategic Plan and looks ahead to the future, we are thrilled to have Gina at the helm. Her leadership will continue to drive positive changes that will elevate our operational excellence, enrich our existing programming, and reinforce WIB's position as a premier organization for women impacting the life sciences and beyond.


Join AURP in Boston for a Deep Dive into Building Communities of Biotech Innovation!

Before the 2023 BIO International Conference begins in Boston, the AURP Bio Health Caucus will focus on building research space supporting communities of bio innovations. 
Developers, A/E firms, researchers, economic development reps, VC firms, and bio innovation district managers will want to attend.

Harsha and Rich 250

Join us for an enlightening episode of BioTalk with Rich Bendis as we explore the pivotal role of patient registries in rare disease research and treatment. Our guest, Harsha Rajasimha, MS, Ph.D., CEO of Jeeva Informatics Solutions and Founder and Executive Chairman of IndoUSrare, shares his extensive experience in clinical genomics data science and precision medicine.

In this episode, Dr. Rajasimha introduces Jeeva Informatics Solutions and IndoUSrare, his non-profit organization. He discusses the importance of patient registries in accelerating rare disease research, the current obstacles in the field, and the potential solutions.

We discuss the role of governments in rare disease research and treatment and the potential for collaboration with non-profits in clinical trials. Finally, Dr. Rajasimha shares the goals of the upcoming Indo-US Rare Summit at the GMU Campus in Arlington, VA.

Tune in for valuable insights from a leader in rare disease research and patient advocacy.

Listen now via your favorite podcast platform


Scheduled for October 29-30, 2023, at the George Mason University Campus in Arlington, VA, the Indo US Bridging RARE Summit 2023 aims to unite the global rare disease community and raise awareness about these conditions. While rare diseases are increasingly understood in the United States and Europe, there remains a lack of awareness in other parts of the world, including India. By addressing this gap, the summit aims to make a positive impact on the lives of 1.5 billion people in India and the global population of 8 billion.

Bringing together leaders representing diverse stakeholders in rare diseases, the summit serves as a platform for knowledge-sharing, exchanging experiences, and fostering collaborations to address the challenges faced by rare disease patients and their families. The event covers crucial themes such as cross-border patient engagement, care pathways encompassing screening, diagnosis, and treatment options, digitization of rare diseases including registries and emerging markets, diversity, equity, and inclusion in the globalization of orphan drugs, orphan drug clinical trials, and regulatory pathways.

IndoUSrare, the organizing body behind the summit, is committed to connecting rare disease patients worldwide and prioritizing education, research, and engagement to enhance their quality of life.

For sponsorship opportunities and event information, interested individuals can contact This email address is being protected from spambots. You need JavaScript enabled to view it. and visit The Indo US Bridging RARE Summit 2023 is an important platform for collaboration and knowledge exchange to make a positive impact on the rare disease community worldwide.

The summit planning committee includes prominent individuals representing various organizations and institutions involved in rare disease research and advocacy. Some of the committee

maximbio logo Logo

ROCKVILLE, Md. May 9, 2023 /PRNewswire/ -- MaximBio® is proud to announce it has signed a new agreement with the National Institutes of Health (NIH) through the Rapid Acceleration of Diagnostics (RADx® ) initiative, continuing a relationship fostered during the height of the COVID-19 pandemic. Building on their previous collaboration which resulted in the successful launch of the MaximBio ClearDetect® COVID-19 Antigen Home Test, the new partnership is centered around development of a COVID-19 and Influenza A/B combo test employing novel Lateral-Flow Technology. This technology, paired with the innovative FiarFly™ analyzer platform, and MaximBio's proprietary manufacturing techniques, results in class-leading assay performance.


Commission also issues Request for Applications for Four Funding Programs for July 13, 2023, Deadline

COLUMBIA, Md. (May 9, 2023) —The Maryland Stem Cell Research Fund (MSCRF) Commission is pleased to announce over $14.1 million in grant awards to promote innovative research that will strengthen and advance stem cell treatments and technologies in Maryland. This is the largest amount awarded to Maryland-based institutions and companies since 2010 and was made possible as a result of increased funding from the State.  This is also the first time that the Commission awarded funding to Maryland-based companies under MSCRF’s new Manufacturing Assistance Program, established to boost cell therapy manufacturing capabilities in the State. 

39 scientists from Maryland-based research institutions and companies will be receiving awards from this round of funding to advance research addressing an array of medical conditions, including cancer, eye, heart, bone, blood, digestive, and central nervous system diseases. Awardees include academic scientists from Johns Hopkins University, University of Maryland, Baltimore County, University of Maryland, College Park, University of Maryland, Baltimore, Lieber Institute for Brain Development, Hugo W. Moser Research Institute at Kennedy Krieger and The Geneva Foundation.  From the commercial sector, awardees include Vita Therapeutics, Inc., Theradaptive, Inc., Caring Cross, Inc., RoosterBio, Inc. and Reprocell U.S.A., Inc.

Rise Therapeutics Logo

Biotech company receives follow-on funding to accelerate ongoing clinical development efforts

COLUMBIA, Md. (May 8, 2023) – TEDCO, Maryland’s economic engine for technology companies, announced a recent Seed Funds investment of $200,000 into Rise Therapeutics, a Maryland-based biotechnology company. TEDCO’s Seed Funds invest in early-stage, technology and life sciences companies and provides access to gap financing.

"We are thrilled to receive this follow-on investment from TEDCO," said Gary Fanger, Ph.D, president and CEO of Rise Therapeutics. "This funding will allow us to accelerate our ongoing clinical development efforts and move closer to bringing our synthetic biology-based immunotherapy drugs to market; we are grateful to TEDCO for their support."

Maxcyte 250

Walking Fish to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to engineer novel B-cell based medicines for the treatment of serious diseases

ROCKVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced the signing of a strategic platform license (SPL) with Walking Fish Therapeutics, Inc. a biotechnology company that is rapidly advancing B cell-based therapeutics.

Under the terms of the agreement, Walking Fish obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is entitled to receive platform licensing fees, clinical milestone payments and sales-based payments.


ROCKVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced the closing of its previously announced public offering of an aggregate of 4,495,825 shares of its common stock (or pre-funded warrants in lieu thereof) and common stock purchase warrants to purchase up to 4,495,825 shares of common stock at a combined public offering price of $0.7785 per share (or pre-funded warrant in lieu thereof) and accompanying warrant. The warrants have an exercise price of $0.7785 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants, and will expire five years from the date of stockholder approval.